@prefix dcterms: .
@prefix this: .
@prefix sub: .
@prefix beldoc: .
@prefix rdfs: .
@prefix rdf: .
@prefix xsd: .
@prefix dce: .
@prefix pav: .
@prefix np: .
@prefix belv: .
@prefix prov: .
@prefix go: .
@prefix Protein: .
@prefix pfh: .
@prefix geneProductOf: .
@prefix hasAgent: .
@prefix mesh: .
@prefix hasAnnotation: .
@prefix species: .
@prefix occursIn: .
@prefix pubmed: .
@prefix orcid: .
sub:Head {
this: np:hasAssertion sub:assertion;
np:hasProvenance sub:provenance;
np:hasPublicationInfo sub:pubinfo;
a np:Nanopublication .
}
sub:assertion {
sub:_1 hasAgent: sub:_2;
a go:0005525 .
sub:_2 geneProductOf: pfh:RAS%20Family;
a Protein: .
sub:_3 occursIn: species:9606;
hasAnnotation: sub:_4;
rdf:object mesh:D010190;
rdf:predicate belv:positiveCorrelation;
rdf:subject sub:_1;
a rdf:Statement .
sub:_4 dcterms:subject "TextLocation";
rdf:value "Review" .
sub:assertion rdfs:label "gtp(p(PFH:\"RAS Family\")) positiveCorrelation path(MESHD:\"Pancreatic Neoplasms\")" .
}
sub:provenance {
beldoc: dce:description "Approximately 2000 hand curated statements drawn from 57 PubMeds.";
dce:rights "Copyright (c) 2011-2012, Selventa. All Rights Reserved.";
dce:title "BEL Framework Small Corpus Document";
dcterms:license "Creative Commons Attribution-Non-Commercial-ShareAlike 3.0 Unported License";
pav:authoredBy sub:_6;
pav:version "1.6" .
sub:_5 prov:value """The considerable attention paid to targeting Ras as a therapeutic strategy is based
on the high incidence of activating ras mutations in human malignancies, including
approximately 22% of non–small-cell lung, 50% of colorectal, and 90% of pancreatic
cancers. 53,60,61""";
prov:wasQuotedFrom pubmed:16170185 .
sub:_6 rdfs:comment "support@belframework.org";
rdfs:label "Selventa" .
sub:assertion prov:hadPrimarySource pubmed:16170185;
prov:wasDerivedFrom beldoc:, sub:_5 .
}
sub:pubinfo {
this: dcterms:created "2014-07-03T14:29:30.375+02:00"^^xsd:dateTime;
pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 .
}